Revolutionary Modified Darobactin: A Breakthrough in the Fight Against Antibiotic-Resistant Bacteria

Antibacterial drugs treat infections, but many bacteria are becoming resistant. New treatments are needed urgently. Researchers have found a promising antibacterial compound called D22, derived from darobactin, a substance from bacteria. This study appears in ACS Infectious Diseases.

The World Health Organization recently updated a list of bacteria that can resist antibiotics, including E. coli, Acinetobacter baumannii, and Pseudomonas aeruginosa. There are few new antibiotics in development targeting these pathogens. Darobactin binds to essential proteins in bacterial cells, leading to their death. Earlier research showed that engineered versions of darobactin, particularly D22, can stop the growth of A. baumannii in lab tests.

In this study, researchers led by Rolf Müller and Jennifer Herrmann tested D22 on various bacterial infections in animals. They found:

• In zebrafish embryos, D22 cleared A. baumannii infections as well as the antibiotic ciprofloxacin.

• In mice, they discovered the best way to deliver D22 was through injection rather than orally.

• D22 limited the growth of P. aeruginosa in thigh tissue infections but did not completely eliminate it.

• Administering D22 four times in 25 hours cleared E. coli in models of severe peritonitis. A single dose also showed some effectiveness. Repeated injections over three days significantly reduced bacterial presence in complicated E. coli urinary tract infections, though gentamicin was more effective in lowering bacterial counts.

These findings suggest that D22 can effectively inhibit serious infections and may lead to future clinical trials as a new option to combat antibiotic resistance.